TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23698211
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution) (S)
Study: 21854650
Drug: Krill oil
Normalized name: Krill oil
DrugBank: Krill oil (DB16615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krill oil (1680 mg EPA+DHA)
Study: 21854650
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil rTAG (1680 mg EPA+DHA)
Study: 21854650
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil EE (1680 mg EPA+DHA)
Study: 17845684
Drug: Serotonin agonists
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin agonists (cisapride and mosapride)
Study: 17845684
Drug: Control agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control agents (dopamine antagonists: metoclopramide and domperidone; opiate agonist: trimebutine)
Study: 7836550
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg)
Study: 24481828
Drug: Ultrasound-guided leukocyte-rich
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided leukocyte-rich PRP injection with standardized eccentric exercises
Study: 1395888
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: no antibiotics given
Study: 31505519
Drug: Escitalopram (SRI)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (SRI) treatment
Study: 28933625
Drug: IIV4 (quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4 (quadrivalent split‐virion inactivated influenza vaccine)
Study: 28933625
Drug: IIV3 (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV3 (licensed split‐virion trivalent inactivated influenza vaccine)
Study: 9862513
Drug: 120FEC with
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120FEC with early primary G-CSF (days 4 to 13)
Study: 9862513
Drug: 60FEC without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60FEC without G-CSF
Study: 8543644
Drug: Aspirin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50 ml solution, concentration 3 mg/ml)
Study: 2093112
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins at doses of 1 g/Kg/day
Study: 2093112
Drug: Randomized therapy
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized therapy (Control)
Study: 272413
Drug: Irrigation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation with Lugol's solution
Study: 29256465
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 0.9% saline solution
Study: 29256465
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml of 0.9% saline solution
Study: 23148500
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Amlodipine and Valsartan)
Study: 16984797
Drug: Antenatal betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal betamethasone treatment (single course)
Study: 14697925
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice daily
Study: 11099808
Drug: Negative patterning
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative patterning (NP) group with letter stimuli (C, N, M, J) reinforced by shock when alone but not in compound.
Study: 11099808
Drug: Negative patterning
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative patterning (NP) group with one pair of letters reinforced as elements but not in compound.
Study: 11099808
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with the same paired‐unpaired sequence but with a compound containing two different letters from the reinforced ones.
Study: 9750603
Drug: Emla cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emla cream + 50 vol% nitrous oxide in oxygen
Study: 16469323
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol therapy
Study: 3524093
Drug: Occlusal adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal adjustment (with 19 patients also receiving splint therapy)
Study: 19745641
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg single dose of triazolam
Study: 19745641
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg divided between 2 equal doses for 60 minutes
Study: 19745641
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg divided among 3 doses for 90 minutes
Study: 15269853
Drug: Coronal preflaring
Normalized name: Corona Udder Butter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronal preflaring using size 25# and 20# ProFile.06 taper NiTi rotary instrument
Study: 16390757
Drug: Risedronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 2.5 mg
Study: 9150326
Drug: L-ASA (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ASA (90 mg x mL(‐1))
Study: 9150326
Drug: Placebo (glycine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glycine, 30 mg x mL(‐1))
Study: 30048027
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (64 mmol daily)
Study: 19031076
Drug: Chloroquine treatment
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine treatment (25 mg/kg body weight, orally on three consecutive days)
Study: 11194533
Drug: 44 g-DG
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 g-DG emulsion
Study: 9258482
Drug: Heparin 50
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 50 IU/kg
Study: 9258482
Drug: Heparin 100
Normalized name: heparin 100 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 100 IU/kg
Study: 24617349
Drug: Isoflavone-rich soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-rich soy protein (25 grams daily, 91 mg of aglycone weight isoflavones: 52 mg genistein, 36 mg daidzein, 3 mg glycitein)
Study: 18549459
Drug: Ibuprofen-Phosphatidylcholine (PC)
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-Phosphatidylcholine (PC)
Study: 21146375
Drug: Early improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early improvement in positive affect during the first week of treatment
Study: 16195989
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin iontophoresis (0.1 ml Humulin R 100 IU/ml diluted 1/10 with 0.9 % saline)
Study: 11805506
Drug: Topical netilmicin
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical netilmicin
Study: 11805506
Drug: Topical netilmicin
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical netilmicin and Gentamicin
Study: 7673657
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 mg
Study: 7673657
Drug: Sertraline 200
Normalized name: sertraline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 200 mg
Study: 2667209
Drug: Campath-1M (10-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath-1M (10-day course postoperatively) + high-dose cyclosporine (17 mg/kg)
Study: 2667209
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (high-dose cyclosporine alone)
Study: 11445789
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (DEX) 0.6 mg/kg, maximum 16 mg for 2 days
Study: 11445789
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (PRED) 2 mg/kg, maximum 60 mg for 5 days
Study: 28945675
Drug: Taurine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (40 mg·kg body mass) in noncaffeine consumers
Study: 28945675
Drug: Taurine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (40 mg·kg body mass) in caffeine consumers deprived of caffeine
Study: 28945675
Drug: Taurine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (40 mg·kg body mass) in noncaffeine consumers (isometric)
Study: 28945675
Drug: Taurine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (40 mg·kg body mass) in caffeine consumers deprived of caffeine (isometric)
Study: 21355378
Drug: Temsirolimus (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (175 mg per week for 3 weeks, followed by 75 mg or 25 mg per week)
Study: 21355378
Drug: Temsirolimus (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (higher dose)
Study: 21355378
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (various other treatments)
Study: 21355378
Drug: Temsirolimus (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (both dose regimens)
Study: 10463902
Drug: Psychological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological treatments (specific details not provided)
Study: 1607498
Drug: Plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange therapy (PE)
Study: 20153888
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg orally twice daily
Study: 28600758
Drug: Pessary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pessary treatment
Study: 22453323
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (pelvic floor muscle training and continence strategies)
Study: 15659145
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg/d
Study: 15866684
Drug: Everolimus 3
Normalized name: everolimus 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3 mg/d
Study: 10221663
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg daily for 8 weeks
Study: 10221663
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg daily for 8 weeks
Study: 2142866
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of epidural sufentanil (5 micrograms/h)
Study: 2142866
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of lumbar epidural morphine (0.5 mg/h)
Study: 673790
Drug: VM 26
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VM 26 (60 mg/m2), methyl‐C.C.N.U. (120 mg/m2) and 5 fluoro‐uracile
Study: 673790
Drug: B.C.G. (simultaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: B.C.G. (simultaneous application)
Study: 31516010
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg per day for six weeks
Study: 25218708
Drug: Ixabepilone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixabepilone (40 mg/m(2) every 21 days)
Study: 25218708
Drug: Ixabepilone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixabepilone (40 mg/m(2) every 21 days) with cetuximab (400 mg/m(2) loading dose, followed by 250 mg/m(2) once weekly)
Study: 17288854
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy and pre-medication (group B)
Study: 11136647
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus fluoxetine
Study: 10440302
Drug: Intravenous mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mitomycin (1.4 mg/m2) and fluorouracil (166.7 mg/m2) twice weekly for 3 weeks after surgery, and oral UFT (uracil plus tegafur, 300 mg daily) for 18 months
Study: 6108445
Drug: Combined vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vaccine and immunoglobulin
Study: 28575646
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol (UP) active-treatment group
Study: 28575646
Drug: Medication-only control
Normalized name: CALCIUM 0.8 ORAL TABLET [OnlyCal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-only control group
Study: 24450301
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg/day for 12 weeks
Study: 23903032
Drug: Zembrin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zembrin (25 mg)
Study: 17702958
Drug: Intraarterial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial infusion of urokinase (UK)
Study: 14671730
Drug: Hypothetical drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical drug trial consent process
Study: 11090788
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/benazepril 10 mg
Study: 1799889
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg
Study: 9234577
Drug: VICOP-B (idarubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VICOP-B (idarubicin 8 mg/sqm)
Study: 9234577
Drug: VICOP-B (idarubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VICOP-B (idarubicin 10 mg/sqm)
Study: 9234577
Drug: VACOP-B (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACOP-B (doxorubicin 50 mg/sqm)
Study: 2125869
Drug: Combined acupuncture
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined acupuncture and medication (ear needling and body needling with half-dosage Innovar and 0.1% lidocaine for scalp infiltration)
Study: 31090748
Drug: Internal hexagon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal hexagon implants (IHC)
Study: 31090748
Drug: External hexagon
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External hexagon implants (EHC)
Study: 27464593
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg every 6 hours)
Study: 26693035
Drug: EECP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EECP therapy
Study: 26932695
Drug: Sham EECP
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham EECP therapy
Study: 22463698
Drug: Triplet antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet antiplatelet therapy (TAT)
Study: 22463698
Drug: Double-dose antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose antiplatelet therapy (DDAT)
Study: 21415052
Drug: sequential monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential monotherapy
Study: 19116965
Drug: step-up combination
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: step-up combination therapy starting with methotrexate
Study: 19116965
Drug: initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: initial combination therapy including tapered high-dose prednisone
Study: 19116965
Drug: initial combination
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: initial combination therapy with methotrexate and infliximab
Study: 18158044
Drug: High-pressure spray
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-pressure spray of 0.3 mL 2% lidocaine using the MadaJet Medical Injector
Study: 18158044
Drug: Traditional vasal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional vasal block with three 1.7-mL ampules of mepivacaine using a 27-gauge needle
Study: 15193965
Drug: Psychotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy group (short-term psychodynamic therapy)
Study: 15193965
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standardized glucocorticoid therapy)
Study: 11779284
Drug: Olanzapine cotherapy
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine cotherapy (5-20 mg/d)
Study: 6097137
Drug: Suxamethonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1.0 mg/kg
Study: 2869713
Drug: Suxamethonium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 0.5 mg/kg
Study: 9807607
Drug: Suxamethonium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 0.25 mg/kg
Study: 9807607
Drug: Suxamethonium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 0.5 mg/kg or more
Study: 7621645
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg daily for 2 days)
Study: 7621645
Drug: Ephedrine sulphate
Normalized name: Ephedrine sulphate
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine sulphate (40 mg daily for 2 days)
Study: 2488093
Drug: Amiodarone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone infusion (10-20 mg/kg in saline infusion within 4 to 10 hours through a central vein)
Study: 2488093
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) infusion (150-300 g of glucose, 25-50 IU of insulin, and 80-120 mEq of KCl in 1000 cc of water at a rate of 1.5-2.0 ml/g/hour)
Study: 320630
Drug: Naproxen-Sodium (NS)
Normalized name: Naproxen Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen-Sodium (NS) 1100 mg
Study: 21829566
Drug: B subunit‐killed
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit‐killed whole‐cell and killed whole‐cell‐only oral cholera vaccines
Study: 19588485
Drug: Baseline insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baseline insulin levels (highest tertile)
Study: 19588485
Drug: Repeated measurements
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated measurements of serum insulin
Study: 17349075
Drug: Blood orange
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL SPRAY [All Clean Premium Hand Sanitizer Blood Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood orange juice (BOJ, 300 ml providing 150 mg vitamin C)
Study: 11587503
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release (SR) paracetamol (Panadol Extend)
Study: 11587503
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) paracetamol (Panadol)
Study: 17083392
Drug: Doxazosin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (2 mg)
Study: 24465671
Drug: Daily repetitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily repetitive training using the rubber hand illusion paradigm
Study: 22179931
Drug: DepoFoam bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DepoFoam bupivacaine 600 mg
Study: 22179931
Drug: bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine HCl 200 mg
Study: 19334061
Drug: MRI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI treatment effects
Study: 17229229
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg (group K)
Study: 17229229
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg (group G)
Study: 17229229
Drug: Ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.25 mg + Granisetron 1.5 mg (group KG)
Study: 11665964
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (prednisolone, methotrexate, and sulfasalazine)
Study: 30657406
Drug: Cocaine/Other Stimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine/Other Stimulant group
Study: 30657406
Drug: Other Stimulant
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Stimulant group (primarily methamphetamine)
Study: 25638351
Drug: Telehealth PTSD
Normalized name: Guaifenesin 100 mg in 5 mL ORAL LIQUID [SelectHealth Tussin DM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth PTSD program, motivational interviewing-based smoking cessation curricula via telehealth device, weekly motivational interviewing counseling phone calls
Study: 22981045
Drug: Plasma Exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Exchange (PE) plus conventional sepsis treatment
Study: 22981045
Drug: Control (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Conventional sepsis treatment only)
Study: 21306237
Drug: Sunitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib at a dose of 37.5 mg per day
Study: 16881243
Drug: Observation tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation tool for evaluating parent-child interaction; details on dosage and duration not applicable.